New drug TQB2102 vs standard therapy for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive and has come back or spread to other parts of the body.
- You have not had any chemotherapy or other cancer treatment for the spread of the disease (except for up to one type of hormone therapy).
- You have a tumor that can be measured on a scan.
- Your cancer has not spread to your brain or spinal cord, or if it has, it is well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new HER2-targeted antibody drug (TQB2102) against standard chemotherapy in people with HER2-low breast cancer that has spread or come back. It aims to see if the new drug works better or is safer than usual chemotherapy.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This study tests a new drug called TQB3126 for people with breast cancer that has worsened after previous treatments. The goal is to see if the drug is safe, how your body processes it, and if it can help shrink or slow the cancer.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.